Millennium Management’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,002,709
| Closed | -$9.14M | – | 6411 |
|
|
2025
Q2 | $9.14M | Buy |
1,002,709
+693,169
| +224% | +$5.1M | ﹤0.01% | 2351 |
|
|
2025
Q1 | $2.46M | Sell |
309,540
-1,314,245
| -81% | -$9.62M | ﹤0.01% | 3583 |
|
|
2024
Q4 | $8.82M | Buy |
1,623,785
+124,720
| +8% | +$762K | ﹤0.01% | 2303 |
|
|
2024
Q3 | $10.8M | Buy |
1,499,065
+1,265,376
| +541% | +$11.6M | 0.01% | 2126 |
|
|
2024
Q2 | $2.54M | Sell |
233,689
-67,464
| -22% | -$864K | ﹤0.01% | 3323 |
|
|
2024
Q1 | $5.64M | Sell |
301,153
-32,050
| -10% | -$739K | ﹤0.01% | 2746 |
|
|
2023
Q4 | $7.22M | Buy |
333,203
+264,417
| +384% | +$5.24M | ﹤0.01% | 2479 |
|
|
2023
Q3 | $1.42M | Sell |
68,786
-349,324
| -84% | -$10.1M | ﹤0.01% | 3898 |
|
|
2023
Q2 | $19.7M | Buy |
418,110
+51,447
| +14% | +$2.56M | 0.01% | 1409 |
|
|
2023
Q1 | $15.4M | Buy |
366,663
+280,979
| +328% | +$12.1M | 0.01% | 1564 |
|
|
2022
Q4 | $3.27M | Buy |
85,684
+39,479
| +85% | +$1.51M | ﹤0.01% | 3146 |
|
|
2022
Q3 | $1.81M | Sell |
46,205
-32,628
| -41% | -$1.26M | ﹤0.01% | 3838 |
|
|
2022
Q2 | $2.55M | Sell |
78,833
-74,853
| -49% | -$2.51M | ﹤0.01% | 3451 |
|
|
2022
Q1 | $5.09M | Buy |
153,686
+126,936
| +475% | +$4.77M | ﹤0.01% | 2920 |
|
|
2021
Q4 | $1.14M | Sell |
26,750
-122,818
| -82% | -$5.14M | ﹤0.01% | 4291 |
|
|
2021
Q3 | $6.63M | Buy |
149,568
+79,583
| +114% | +$3.65M | ﹤0.01% | 2553 |
|
|
2021
Q2 | $3.98M | Buy |
69,985
+52,348
| +297% | +$3.7M | ﹤0.01% | 3067 |
|
|
2021
Q1 | $1.32M | Sell |
17,637
-1,090
| -6% | -$89.4K | ﹤0.01% | 3931 |
|
|
2020
Q4 | $1.62M | Sell |
18,727
-188,024
| -91% | -$13.9M | ﹤0.01% | 3399 |
|
|
2020
Q3 | $12.6K | Sell |
206,751
-94,465
| -31% | -$4.79M | 0.02% | 1077 |
|
|
2020
Q2 | $12.5M | Sell |
301,216
-346,254
| -53% | -$12.6M | 0.02% | 1058 |
|
|
2020
Q1 | $18.6M | Buy |
647,470
+584,336
| +926% | +$33.8M | 0.04% | 485 |
|
|
2019
Q4 | $4.56M | Buy |
63,134
+34,637
| +122% | +$4.26M | 0.01% | 2012 |
|
|
2019
Q3 | $4M | Buy |
+28,497
| New | +$4.77M | 0.01% | 1988 |
|
|
2019
Q1 | – | Sell |
-128,822
| Closed | -$12.3M | – | 4282 |
|
|
2018
Q4 | $12.3M | Sell |
128,822
-229,877
| -64% | -$26.3M | 0.02% | 998 |
|
|
2018
Q3 | $50.7M | Sell |
358,699
-21,205
| -6% | -$3.27M | 0.06% | 406 |
|
|
2018
Q2 | $59.5M | Buy |
379,904
+327,312
| +622% | +$51.4M | 0.08% | 337 |
|
|
2018
Q1 | $8.47M | Buy |
52,592
+1,747
| +3% | +$297K | 0.01% | 1446 |
|
|
2017
Q4 | $8.38M | Buy |
+50,845
| New | +$4.93M | 0.01% | 1442 |
|
|
2017
Q2 | – | Sell |
-5,308
| Closed | -$377K | – | 3807 |
|
|
2017
Q1 | $377K | Sell |
5,308
-270,819
| -98% | -$15.9M | ﹤0.01% | 2945 |
|
|
2016
Q4 | $14.1M | Sell |
276,127
-446,265
| -62% | -$21M | 0.03% | 741 |
|
|
2016
Q3 | $33.3M | Buy |
722,392
+6,856
| +1% | +$279K | 0.06% | 378 |
|
|
2016
Q2 | $21.6M | Buy |
715,536
+192,075
| +37% | +$6.4M | 0.05% | 494 |
|
|
2016
Q1 | $16.8M | Buy |
523,461
+4,723
| +0.9% | +$166K | 0.04% | 559 |
|
|
2015
Q4 | $30.2M | Buy |
+518,738
| New | +$25.7M | 0.06% | 418 |
|
|
2015
Q3 | – | Sell |
-9,381
| Closed | -$685K | – | 3695 |
|
|
2015
Q2 | $685K | Sell |
9,381
-138,259
| -94% | -$8.89M | ﹤0.01% | 2475 |
|
|
2015
Q1 | $7.42M | Buy |
+147,640
| New | +$6.35M | 0.01% | 1202 |
|
|
2014
Q4 | – | Sell |
-80,078
| Closed | -$2.52M | – | 4225 |
|
|
2014
Q3 | $2.52M | Buy |
+80,078
| New | +$2.32M | 0.01% | 1717 |
|
Other funds holding SAGE
IA
HNB
Millennium Management's SAGE Position: Q3 2025 in Review
Millennium Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 1,002,709 shares — an estimated $9.14M sold.
Millennium Management first reported a position in SAGE in Q3 2014 and held it in 38 quarters. The position peaked at $59.5M in Q2 2018. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- Millennium Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- Millennium Management sold 1,002,709 Sage Therapeutics shares in Q3 2025, an estimated $9.14M.
- Millennium Management first reported a position in Sage Therapeutics in Q3 2014 and held it in 38 quarters.
- Millennium Management's Sage Therapeutics position peaked at $59.5M in Q2 2018.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on Millennium Management's 13F filing for Q3 2025, filed 14 Nov 2025.